Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203

Leukemia. 2025 Mar;39(3):752-754. doi: 10.1038/s41375-024-02512-3. Epub 2025 Jan 27.

Megan Othus¹, Guillermo Garcia-Manero², Frederick R Appelbaum^{3

4}, Harry P Erba⁵, Eliana Dietrich⁶, Suravi Raychaudhuri^{3

4}, Jacob Appelbaum^{3

4}, Elihu Estey^{3

4}, Mary-Elizabeth Percival^{3

4}

¹ Public Health Division and SWOG Statistical Center, Fred Hutchinson Cancer Center, Seattle, WA, USA. mothus@fredhutch.org.
² Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
⁵ Duke University, Durham, NC, USA.
⁶ Public Health Division and SWOG Statistical Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.

No abstract available

Grants and funding